Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder following lung transplantation is more commonly of host origin

Archives of Pathology and Laboratory Medicine

Volumn 130, Issue 2, 2006, Pages 176-180

  Peterson, Michael R ^a   Emery, Shawn C ^a   Yung, Gordon L ^a   Masliah, Eliezer ^a   Yi, Eunhee S ^a  

^a UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; LATENT MEMBRANE PROTEIN 1;

ADULT; AGED; AUTOPSY; BONE MARROW TRANSPLANTATION; CASE REPORT; CONTROLLED STUDY; DISEASE COURSE; DONOR; EPSTEIN BARR VIRUS; FEMALE; GENOTYPE; HOST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG TRANSPLANTATION; LYMPHOID CELL; LYMPHOPROLIFERATIVE DISEASE; MALE; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; RECIPIENT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW;

AGED; CYTOCHROME P-450 CYP2D6; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POSTOPERATIVE COMPLICATIONS; TISSUE DONORS; VIRAL MATRIX PROTEINS;

EID: 32544461137     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Harris NL, Swerdlow SH, Frizzera C, Knowles DM. Post-transplant lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:264-269.
2. World Health Organization Classification of Tumours; vol 3.
3. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol. 1988;133:173-192.
4. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol. 2000;24:375-385.
5. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood. 1988;72:520-529.
6. Chadburn A, Suciu-Foca N, Cesarman E, Reed E, Michler RE, Knowles DM. Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. Am J Pathol. 1995;147:1862-1870.
7. Randhawa PS, Yousem SA. Epstein-Barr virus-associated lymphoproliferative disease in a heart-lung allograft: demonstration of host origin by restriction fragment-length polymorphism analysis. Transplantation. 1990;49:126-130.
8. Caillard S, Pencreach E, Braun L, et al. Simultaneous development of lymphoma in recipients of renal transplants from a single donor: donor origin confirmed by human leukocyte antigen staining and microsatellite analysis. Transplantation. 2005;79:79-84.
9. Larson RS, Scott MA, McCurley TL, Vnencak-Jones CL. Microsatellite analysis of posttransplant lymphoproliferative disorders: determination of donor/recipient origin and identification of putative lymphomagenic mechanism. Cancer Res. 1996;56:4378-4381.
10. Nuckols JD, Baron PW, Stenzel TT, et al. The pathology of liver-localized post-transplant lymphoproliferative disease: a report of three cases and a review of the literature. Am J Surg Pathol. 2000;24:733-741.
11. Renoult E, Aymard B, Gregoire MJ, et al. Epstein-Barr virus lymphoproliferative disease of donor origin after kidney transplantation: a case report. Am J Kidney Dis. 1995;26:84-87.
12. Spiro IJ, Yandell DW, Li C, et al. Brief report: lymphoma of donor origin occurring in the porta hepatis of a transplanted liver. N Engl J Med. 1993;329:27-29.
13. Petit B, Le Meur Y, Jaccard A, et al. Influence of host-recipient origin on clinical aspects of posttransplantation lymphoproliferative disorders in kidney transplantation. Transplantation. 2002;73:265-271.
14. Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I. Post-transplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol. 1995;103:748-755.
15. Gulley ML, Swinnen LJ, Plaisance KT Jr, Schnell C, Grogan TM, Schneider BG. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation. 2003;76:959-964.
16. Saitoh T, Xia Y, Chen X, et al. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Ann Neurol. 1995;37:110-112.
17. Griffais R, Andre PM, Thibon M. K-tuple frequency in the human genome and polymerase chain reaction. Nucleic Acids Res. 1991;19:3887-3891.
18. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
19. Levine SM, Angel L, Anzueto A, et al. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients. Chest. 1999;116:1273-1277.
20. Ramalingam P, Rybicki L, Smith MD, et al. Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience. Mod Pathol. 2002;15:647-656.
21. Reams BD, McAdams HP, Howell DN, Steele MP, Davis RD, Palmer SM. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest. 2003;124:1242-1249.